Search results
Showing 301 to 315 of 877 results for community guidance
This guideline covers targeted interventions to prevent misuse of drugs, including illegal drugs, ‘legal highs’ and prescription-only medicines. It aims to prevent or delay harmful use of drugs in children, young people and adults who are most likely to start using drugs or who are already experimenting or using drugs occasionally.
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]
In development Reference number: GID-TA11429 Expected publication date: 09 September 2026
This quality standard covers increasing the uptake of flu vaccination among people who are eligible. It describes high-quality care in priority areas for improvement.
This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots, including deep vein thrombosis and pulmonary embolism) in people aged 16 and over in hospital. It aims to help healthcare professionals identify people most at risk and describes interventions that can be used to reduce the risk of VTE.
COVID-19 rapid guideline: haematopoietic stem cell transplantation (NG164)
The purpose of this guideline is to maximise the safety of patients who need haemopoietic stem cell transplantation and make the best use of NHS resources, while protecting staff from infection.
Show all sections
In development Reference number: GID-TA11554 Expected publication date: TBC
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448]
In development Reference number: GID-TA11564 Expected publication date: TBC
This indicator covers tooth extractions due to decay for children admitted as inpatients to hospital, aged 10 years and under. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Generalised anxiety disorder and panic disorder in adults: management (CG113)
This guideline covers the care and treatment of people aged 18 and over with generalised anxiety disorder (chronic anxiety) or panic disorder (with or without agoraphobia or panic attacks). It aims to help people achieve complete relief of symptoms (remission), which is associated with better functioning and a lower likelihood of relapse.
Tell us what matters to you, your organisation or your community.
Tell us what matters to you, your organisation or your community.
Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)
Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection
Self-harm: assessment, management and preventing recurrence (NG225)
This guideline covers assessment, management and preventing recurrence for children, young people and adults who have self-harmed. It includes those with a mental health problem, neurodevelopmental disorder or learning disability and applies to all sectors that work with people who have self-harmed.
Our associates help us to support high quality, safe, cost-effective prescribing and medicines optimisation.
In a virtual ward setting, you make assessments at home to support clinical decision-making. Our guidance can help you give advice by highlighting areas to consider and standards of care.